Breaking News Instant updates and real-time market news.

XLRN

Acceleron

$36.04

-0.08 (-0.22%)

, ARQL

ArQule

$5.00

-0.31 (-5.84%)

04:55
06/17/18
06/17
04:55
06/17/18
04:55

European Hematology Association to hold a conference

23rd Congress of the EHA will be held in Stockholm, Sweden on June 14-17.

XLRN

Acceleron

$36.04

-0.08 (-0.22%)

ARQL

ArQule

$5.00

-0.31 (-5.84%)

EPZM

Epizyme

$15.00

-0.85 (-5.36%)

KPTI

Karyopharm

$18.65

0.6 (3.32%)

APLS

Apellis

$22.34

0.26 (1.18%)

BLUE

Bluebird Bio

$182.75

-13.95 (-7.09%)

TGTX

TG Therapeutics

$13.75

-0.05 (-0.36%)

  • 20

    Jun

XLRN Acceleron
$36.04

-0.08 (-0.22%)

05/09/18
HCWC
05/09/18
NO CHANGE
Target $69
HCWC
Buy
Acceleron price target raised to $69 from $62 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Acceleron Pharma to $69 following the company's Q1 results. With Luspatercept data coming soon the analyst keeps a Buy rating on the shares.
03/01/18
SBSH
03/01/18
NO CHANGE
Target $63
SBSH
Buy
Acceleron price target raised to $63 from $44 at Citi
Citi analyst Robyn Karnauskas raised her price target for Acceleron Pharma to $63 saying the upcoming luspatercept pivotal data is likely to be positive. The analyst increased her probability of success for luspatercept in beta-thalassemia and ring sideroblast-positive myelodysplastic syndromes to 100% from 80%. She expects positive results from the Phase 3 Medalist and Believe trials when they read out top-line data mid-2018 and keeps a Buy rating on Acceleron.
02/28/18
PIPR
02/28/18
NO CHANGE
Target $53
PIPR
Overweight
Acceleron price target raised to $53 from $40 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Acceleron Pharma to $53 and keeps an Overweight rating on the shares following the company's Q4 results. Acceleron ended 2017 with cash of $373M guided to fund the company into 2021, Tenthoff tells investors in a research note.
02/26/18
JPMS
02/26/18
UPGRADE
Target $52
JPMS
Overweight
JPMorgan upgrades Acceleron to Overweight ahead of luspatercept data
JPMorgan analyst Eric Joseph upgraded Acceleron Pharma to Overweight from Neutral and raised his price target for the shares to $52 from $33 ahead of pivotal data for lead asset luspatercept in myelodysplastic syndrome and beta-thalassemia. The stock closed Friday up 91c to $42.91. The mid-year data readout mark a "potentially transformational catalyst" for Acceleron in transitioning from a development to commercial stage company, Joseph tells investors in a research note. Based on "maturing" Phase 2 datasets and physician feedback, the analyst sees high probabilities of trial success and ultimately approval in each of the indications.
ARQL ArQule
$5.00

-0.31 (-5.84%)

04/05/18
LEER
04/05/18
UPGRADE
Target $5
LEER
Outperform
ArQule upgraded to Outperform from Market Perform at Leerink
Leerink analyst Jonathan Chang upgraded ArQule to Outperform from Market Perform and raised his price target on the shares to $5 from $1.50 after assuming coverage of the stock. The analyst has a positive view on the stock ahead of multiple clinical catalysts expected in 2018 and view the risk/reward profile as attractive.
04/17/18
ROTH
04/17/18
NO CHANGE
Target $6
ROTH
Buy
ArQule price target raised to $6 after AACR meeting at Roth Capital
Roth Capital analyst Jotin Marango noted that ArQule presented clinical data on its BTK inhibitor ARQ 531 and its AKT inhibitors Miransertib and ARQ 751 at the AACR meeting this weekend and subsequently reported the outlicensing of its FGFR inhibitor derazantinib. He believes that over the last few days the company has been able monetize its "riskier and costlier program" while presenting data that build material value into its rising programs, Marango tells investors. He raised his price target on ArQule shares to $6 from $5 and keeps a Buy rating on the stock.
06/11/18
OPCO
06/11/18
INITIATION
Target $7
OPCO
Outperform
ArQule initiated with an Outperform at Oppenheimer
Oppenheimer initiated ArQule with an Outperform and $7 price target.
06/12/18
06/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. InterDigital (IDCC) initiated with a Buy at Roth Capital. 2. Weight Watchers (WTW) initiated with an Overweight at JPMorgan and a Buy at DA Davidson. 3. Franklin Electric (FELE) initiated with a Neutral at DA Davidson. 4. ArQule (ARQL) initiated with an Outperform at Oppenheimer. 5. comScore (SCOR) initiated with a Buy at Loop Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
EPZM Epizyme
$15.00

-0.85 (-5.36%)

05/18/18
WEDB
05/18/18
NO CHANGE
Target $25
WEDB
Outperform
Epizyme price target raised to $25 from $20 at Wedbush
Wedbush analyst David Nierengarten raised his price target on Epizyme to $25 from $20, telling investors in a research note that abstracts from The European Hematology Association show responses are deepening in the EZH2-wt follicular lymphoma cohort, increasing his confidence that tazemetostat will find a broad use in FL regardless of mutation status. However, the analyst noted that he is "less certain" on the future for the drug in mesothelioma, where low response rates seen in a Phase 2 trial indicate a more challenging path forward.
04/24/18
JMPS
04/24/18
NO CHANGE
Target $28
JMPS
Outperform
Epizyme hold news has 'number of mitigating factors,' says JMP Securities
JMP Securities analyst Michael GKing noted the FDA has issued a partial clinical hold for clinical trials evaluating Epizyme's tazemetostat, but he sees "a number of mitigating factors" to this negative news. Those include the fact that the Phase 2 FL and DLBCL trials are mostly enrolled and that the Phase 2 study in mesothelioma and epithelioid sarcoma are already fully enrolled. He sees it making sense that the FDA would issue a hold "out of an abundance of caution," given the pediatric indication, but he maintains an Outperform rating and $28 price target on Epizyme shares.
04/24/18
RHCO
04/24/18
NO CHANGE
Target $20
RHCO
Buy
Epizyme price target lowered to $20 from $27 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Epizyme to $20, saying that while the FDA hold on the tazemetostat trial should be brief, the 20% decline in the stock price afterhours justifies a more conservative target. In light of the hold, Lawson adds that he is also reducing his probability of success for tazemetostat to 60% from 65% and penetration to 75% from 85% in EZH2 mutant FL, while also reducing the probability of success in INI1-negative solid tumors to 60% from 85% and the penetration to 75% from 85%. The analyst keeps his Buy rating on Epizyme.
05/17/18
JEFF
05/17/18
NO CHANGE
Target $27
JEFF
Buy
Epizyme's tazemetostat still looks 'approvable and attractive,' says Jefferies
After abstracts were released ahead of the ASCO meeting for new and updated Phase II tazemetostat data in mesothelioma and "more importantly" follicular lymphoma data to be presented at the EHA meeting, Jefferies analyst Michael Yee said the new lymphoma abstract data "looks solid." The high responses rates support Yee's view that tazemetostat looks like "an approval and attractive cancer drug," he tells investors. Yee keeps a Buy rating on Epizyme with a $27 price target.
KPTI Karyopharm
$18.65

0.6 (3.32%)

05/24/18
05/24/18
DOWNGRADE
Target $19

Neutral
Karyopharm downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst David Nierengarten downgraded Karyopharm to Neutral from Outperform on valuation. The analyst also lowered his price target on the shares to $19 from $20 as he updates his model for the company's offering and for a somewhat shorter duration of therapy based on the STORM duration of response of 4.4 months.
05/24/18
WEDB
05/24/18
DOWNGRADE
WEDB
Neutral
Karyopharm downgraded to Neutral from Outperform at Wedbush
05/24/18
HCWC
05/24/18
NO CHANGE
Target $30
HCWC
Buy
H.C. Wainwright remains bullish Karyopharm after STORM data, license deal
H.C. Wainwright analyst Edward White reiterates a Buy rating and $30 price target for Karyopharm, while pointing out that recent positive Phase 2b STORM data confirmed his expectations for the success of selinexor. The company expects a NDA submission for an accelerated approval of selinexor in patients with penta-refractory multiple myeloma in 2H18, he says, adding that he estimates the addressable peak market size for this population is over $500M in the U.S. The analyst also notes that the company has announced an exclusive license agreement for the development and commercialization of selinexor, eltanexor, verdinexor and KPT-9274 with Antengene Corporation.
05/24/18
05/24/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AbbVie (ABBV) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jami Rubin citing share outperformance. 2. Petrobras (PBR) downgraded to Equal Weight from Overweight at Morgan Stanley, to Neutral from Outperform at Credit Suisse, to Neutral from Buy at BofA/Merrill, and to Market Perform from Outperform at Itau BBA. 3. Karyopharm (KPTI) downgraded to Neutral from Outperform at Wedbush with analyst David Nierengarten citing valuation. 4. Vermillion (VRML) downgraded to Hold from Buy at Canaccord. 5. Generac (GNRC) downgraded to Neutral from Outperform at Baird. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
APLS Apellis
$22.34

0.26 (1.18%)

12/04/17
EVER
12/04/17
INITIATION
Target $49
EVER
Outperform
Apellis initiated with an Outperform at Evercore ISI
Evercore ISI analyst Umer Raffat initiated Apellis with an Outperform and $49 price target.
04/12/18
RILY
04/12/18
DOWNGRADE
Target $27
RILY
Neutral
Apellis downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar downgraded Apellis Pharmaceuticals to Neutral with an unchanged price target of $27. The analyst cites valuation for the downgrade with the shares up 95% in two months.
05/23/18
CANT
05/23/18
INITIATION
Target $52
CANT
Overweight
Apellis initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros started Apellis with an Overweight rating and $52 price target.
02/08/18
RILY
02/08/18
INITIATION
Target $27
RILY
Buy
Apellis initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Apellis Pharmaceuticals with a Buy rating and $27 price target.
BLUE Bluebird Bio
$182.75

-13.95 (-7.09%)

06/04/18
CANT
06/04/18
NO CHANGE
Target $122
CANT
Underweight
Bluebird Bio shares remain 'significantly overvalued,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros reiterates an Underweight rating on shares of Bluebird Bio with a $122 price target following updates presented at the American Society of Clinical Oncology Conference. The Phase 1 study of bb2121 in patients with relapsed/refractory multiple myeloma "strongly support" use of the drug in a difficult-to-treat setting, Piros tells investors in a research note. The analyst, however, believes shares of Bluebird Bio are "significantly overvalued" amid "lofty investor expectations."
06/04/18
GSCO
06/04/18
NO CHANGE
GSCO
Bluebird Bio data solid, own into EHA, says Goldman Sachs
Goldman Sachs analyst Salveen Richter said Bluebird Bio presented solid bb2121 data at ASCO, significantly exceeding the clinical bar set by standard-of-care Darzalex in a heavily pretreated population, with highly positive KOL feedback. Richter recommends owning Bluebird into the European Hematology Association meeting, June 14-17, where he expects proof-of-concept for LentiGlobin in severe sickle cell disease (SCD), a key potential driver, and pivotal transfusion-dependent beta-thalassemia results to support a 2H 2018 EU regulatory filing. The analyst rates Bluebird a Conviction Buy with a $301 price target.
06/04/18
MSCO
06/04/18
NO CHANGE
Target $190
MSCO
Equal Weight
Bluebird Bio PFS data met, but did not top, expectations, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that updated bb2121 data presented at ASCO demonstrated a median Progression Free Survival of 11.8 months, which he said is in-line, but not above, investor expectations of about 12 months. Given the data appears generally in-line with expectations, Harrison said he would expect Bluebird Bio shares "to be flat or face slight pressure on the data." He keeps an Equal Weight rating on the stock, which is down $7.40, or 4%, to $175 in pre-market trading.
06/15/18
PIPR
06/15/18
NO CHANGE
PIPR
Overweight
Bluebird Bio update in sickle cell patients 'very positive, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren believe Bluebird Bio's update on LentiGlobin gene therapy in patients with severe sickle cell disease was "very positive," attributing the pullback in the stock to expectations that remain high. Investors have been more skeptical of the sickle cell opportunity than TDT, but Van Buren thinks that will change as the patients continue making progress and more have positive responses, he tells investors. The analyst, who sees a $2B global opportunity in TDT and a similar but underappreciated opportunity in SCD, keeps an Overweight rating on Bluebird Bio shares.
TGTX TG Therapeutics
$13.75

-0.05 (-0.36%)

03/08/18
RHCO
03/08/18
NO CHANGE
Target $38
RHCO
Buy
TG Therapeutics price target increased to $38 from $36 at SunTrust
04/24/18
HCWC
04/24/18
NO CHANGE
Target $38
HCWC
Buy
TG Therapeutics updated data 'remains robust,' says H.C. Wainwright
The updated data from TG Therapeutics' (TGTX) Phase 2 study of ublituximab in patients with relapsing forms of multiple sclerosis "remains robust and consistent with previous updates," H.C. Wainwright analyst Edward White tells investors in a research note. The updated data demonstrates continued safety and efficacy with ublituximab, with sustained 99% median B-cell depletion and 100% reduction in T1 Gd-enhancing lesions, the analyst writes. More importantly, White notes, is that an annualized relapse rate of 0.05 was observed at week 24 in 48 patients, which so far is below the ARR observed with Roche's (RHBBY) Ocrevus, the only approved anti-CD20 monoclonal antibody on the market for multiple sclerosis. The analyst views this morning's data positive and reiterates a Buy rating on TG Therapeutics with a $38 price target.
06/04/18
HCWC
06/04/18
NO CHANGE
Target $38
HCWC
Buy
TG Therapeutics ASCO update an incremental positive, says H.C. Wainwright
H.C. Wainwright analyst Edward White said he believes TG Therapeutics' poster presentation at ASCO further supports his view that umbralisib is a differentiated oral PI3K delta inhibitor. White, who notes that the Phase 3 UNITY-CLL trial remains on target for ORR data this summer, keeps a Buy rating and $38 price target on TG Therapeutics shares.
03/08/18
HCWC
03/08/18
NO CHANGE
Target $38
HCWC
Buy
TG Therapeutics price target raised to $38 from $33 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for TG Therapeutics to $38 following the company's Q4 results. The analyst believes TG has a cash runway "well into" 2019 and he keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

, AGN

Allergan

$191.34

-1.11 (-0.58%)

04:55
09/22/18
09/22
04:55
09/22/18
04:55
Conference/Events
European Society of Retina Specialists to hold a conference »

18th Congress of EURETINA…

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

AGN

Allergan

$191.34

-1.11 (-0.58%)

ALIM

Alimera Sciences

$1.07

(0.00%)

BABY

Natus Medical

$34.45

-0.2 (-0.58%)

BHC

Bausch Health

$24.92

-0.07 (-0.28%)

BAYRY

Bayer

$0.00

(0.00%)

ELXMF

Ellex Medical Lasers

$0.00

(0.00%)

GKOS

Glaukos

$58.78

-1.69 (-2.79%)

IRIX

IRIDEX

$6.52

0.08 (1.24%)

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

NITE

Nightstar Therapeutics

$25.64

-1.71 (-6.25%)

NVS

Novartis

$85.46

-0.505 (-0.59%)

OCUL

Ocular Therapeutix

$6.45

0.03 (0.47%)

RHHBY

Roche

$0.00

(0.00%)

SHPG

Shire

$178.32

-1.68 (-0.93%)

STAA

STAAR Surgical

$47.00

-0.9 (-1.88%)

TMDI

Titan Medical

$2.24

0.02 (0.90%)

TTNP

Titan Pharmaceuticals

$0.22

-0.2833 (-56.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 09

    Oct

  • 16

    Oct

  • 22

    Oct

  • 28

    Oct

  • 29

    Oct

  • 15

    Nov

  • 27

    Nov

  • 21

    Dec

  • 28

    Dec

  • 15

    Feb

  • 25

    Feb

CDTI

CDTi

$0.34

0.01 (3.08%)

18:15
09/21/18
09/21
18:15
09/21/18
18:15
Hot Stocks
CDTi sees September 21 as effective date of reverse stock split »

CDTi Advanced Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUK

Duke Energy

$79.82

-0.81 (-1.00%)

18:08
09/21/18
09/21
18:08
09/21/18
18:08
Hot Stocks
Duke Energy restored nearly 1.8M outages in NC, SC during past week »

Duke Energy crews today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 11

    Nov

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

18:01
09/21/18
09/21
18:01
09/21/18
18:01
Hot Stocks
Johnson & Johnson's Janssen discloses phase 3 study results of Esketamine »

The Janssen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

UAL

United Continental

$89.94

0.8 (0.90%)

17:39
09/21/18
09/21
17:39
09/21/18
17:39
Periodicals
United pilots refuse contract changes on regional routes, Reuters says »

United Airlines pilots…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

, XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

17:36
09/21/18
09/21
17:36
09/21/18
17:36
General news
Week ending ETF Scorecard: Materials outperform, Utlilites slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

IYR

DJ US Real Estate Index Fund

$81.88

-0.06 (-0.07%)

XLP

Consumer Staples Sector SPDR

$55.02

0.1285 (0.23%)

XLY

Consumer Discretionary Sector SPDR

$116.98

-0.4288 (-0.37%)

XLB

S&P Select Materials SPDR

$60.54

-0.1312 (-0.22%)

XLF

Financial Select Sector

$28.73

-0.1175 (-0.41%)

XLV

Health Care Select Sector SPDR

$94.26

0.1571 (0.17%)

XLK

Technology Select Sector SPDR

$74.68

-0.2056 (-0.27%)

XLI

Industrial Select Sector SPDR

$79.71

0.2338 (0.29%)

GLD

SPDR Gold Trust

$113.48

-0.77 (-0.67%)

SLV

iShares Silver Trust

$13.44

-0.01 (-0.07%)

USO

United States Oil Fund

$14.95

0.145 (0.98%)

UNG

United States Natural Gas Fund

$24.60

0.235 (0.96%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.24

0.05 (0.06%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$114.72

0.04 (0.03%)

TLT

iShares 20+ Year Treasury Bond Fund

$117.12

-0.02 (-0.02%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.00

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.05

0.02 (0.02%)

IWD

iShares Russell 1000 Value

$129.51

0.13 (0.10%)

IWF

iShares Russell 1000 Growth

$155.30

-0.55 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHGI

One Horizon Group

$0.18

-0.0088 (-4.63%)

17:34
09/21/18
09/21
17:34
09/21/18
17:34
Syndicate
Breaking Syndicate news story on One Horizon Group »

One Horizon Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTX

Cytori Therapeutics

$0.41

-0.033 (-7.38%)

17:31
09/21/18
09/21
17:31
09/21/18
17:31
Syndicate
Breaking Syndicate news story on Cytori Therapeutics »

Cytori Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEM

Newmont Mining

$31.56

0.05 (0.16%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Syndicate
Breaking Syndicate news story on Newmont Mining »

Newmont Mining files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Oct

CB

Chubb

$139.87

-0.05 (-0.04%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Hot Stocks
Chubb CEO Greenberg sells $8.6M in common stock »

Chubb CEO Evan Greenberg…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTVT

vTv Therapeutics

$0.80

0.0096 (1.21%)

17:21
09/21/18
09/21
17:21
09/21/18
17:21
Hot Stocks
vTv says FDA advised that azeliragon efficacy be shown in at least 2 trials »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VYGR

Voyager Therapeutics

$18.21

-0.27 (-1.46%)

17:17
09/21/18
09/21
17:17
09/21/18
17:17
Hot Stocks
Breaking Hot Stocks news story on Voyager Therapeutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNRC

Generac

$57.99

-0.02 (-0.03%)

17:16
09/21/18
09/21
17:16
09/21/18
17:16
Hot Stocks
Generac announces new $250M share repurchase program »

The company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

, IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

17:13
09/21/18
09/21
17:13
09/21/18
17:13
Conference/Events
Independent Bank to host special shareholder meeting »

Special Shareholder…

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

HRS

Harris

$164.33

1.685 (1.04%)

17:13
09/21/18
09/21
17:13
09/21/18
17:13
Hot Stocks
Harris awarded $255.4M Department of Defense contract »

Harris Corp has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PMBC

Pacific Mercantile Bancorp

$9.25

-0.5 (-5.13%)

17:10
09/21/18
09/21
17:10
09/21/18
17:10
Hot Stocks
Breaking Hot Stocks news story on Pacific Mercantile Bancorp »

FJ Capital Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

WSC

WillScot

$17.10

-0.05 (-0.29%)

17:10
09/21/18
09/21
17:10
09/21/18
17:10
Syndicate
Breaking Syndicate news story on WillScot »

WillScot files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTEA

DAVIDsTEA

$2.50

-0.9 (-26.47%)

17:09
09/21/18
09/21
17:09
09/21/18
17:09
Hot Stocks
Breaking Hot Stocks news story on DAVIDsTEA »

TDM Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYT

New York Times

$23.45

0.3 (1.30%)

, EXPE

Expedia

$133.73

-0.77 (-0.57%)

17:08
09/21/18
09/21
17:08
09/21/18
17:08
Hot Stocks
Expedia president Bhutani joins New York Times board »

The New York Times…

NYT

New York Times

$23.45

0.3 (1.30%)

EXPE

Expedia

$133.73

-0.77 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

, GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

17:08
09/21/18
09/21
17:08
09/21/18
17:08
Conference/Events
Guaranty Bancorp to host special shareholder meeting »

Special Shareholder…

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

, ANDV

Andeavor

$154.80

2.19 (1.44%)

17:01
09/21/18
09/21
17:01
09/21/18
17:01
Conference/Events
Andeavor to host special shareholder meeting »

Special Shareholder…

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

ANDV

Andeavor

$154.80

2.19 (1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

ANDV

Andeavor

$154.80

2.19 (1.44%)

, MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

16:59
09/21/18
09/21
16:59
09/21/18
16:59
Conference/Events
Marathon Petroleum to host special shareholder meeting »

Special Shareholder…

ANDV

Andeavor

$154.80

2.19 (1.44%)

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

EPRT

Essential Properties Realty Trust

$14.49

-0.015 (-0.10%)

16:45
09/21/18
09/21
16:45
09/21/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Essential Properties Realty Trust »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBSI

Barrett Business

$63.67

0.04 (0.06%)

16:43
09/21/18
09/21
16:43
09/21/18
16:43
Hot Stocks
SEC says Barrett Business to pay $1.5M penalty over improper accounting »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIGA

Siga Technologies

$7.25

0.5 (7.41%)

16:42
09/21/18
09/21
16:42
09/21/18
16:42
Conference/Events
Siga Technologies to host business news update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.